TTD Faces Earnings with Index Demotion Behind It and Bears Still Positioned

Short interest remains the dominant technical fact about this stock. Bears hold approximately 18.7% of the free float, a level that qualifies as high by any conventional measure. That figure has edged slightly lower over the past week, down about 1.4%, and has pulled back meaningfully from the mid-September peak when shorts held closer to 89 million shares. The borrow market, however, offers no sign of stress: availability has loosened dramatically since the September forced-selling period, when it compressed to a 52-week low of 288%, and now reads 1,558%. Borrowing costs have fallen 22% over the week to 0.30%. With availability loose and cost to borrow near the floor, there is no meaningful squeeze pressure in the lending market, shorts are comfortable and well-financed ahead of the print.

Options positioning tells an almost opposite story to the bearish short book. The put/call ratio has fallen to 0.32, the lowest reading of the past 52 weeks and nearly 1.7 standard deviations below its 20-day average of 0.36. In a stock this heavily shorted, call-heavy positioning of this magnitude points to traders buying upside exposure, either as cheap lottery tickets ahead of earnings or as a hedge against a short-covering move. Both the PCR and the trend in short interest declining from peak suggest the market is not uniformly bearish, even if the headline SI level remains high.

The Street reflects the damage done by the August results. Revenue growth slowed from 27% in Q3 2024 to just 3% in Q2 2026, the quarter's $715 million print missed estimates, and Q3 guidance of at least $650 million implies the company's first year-over-year revenue decline since going public. The response was swift: multiple firms cut ratings and targets after the August print, with DA Davidson downgrading to Neutral and cutting from $29 to $16, Citigroup moving to Sell with an $11 target, and Guggenheim moving to Neutral at $12. UBS held its Buy but dropped its target from $28 to $16. The mean price target now stands near $13.57, close to where the stock is trading at $12.08, leaving limited implied upside from the Street consensus. The bear case centres on three CFO changes since January, the departure of the CRO, slowing agency spend, CPG budget pressure, and competition from Amazon and Google eating at take rates. EBITDA margins are compressing, with Q3 guidance implying roughly 24.6%. Bulls point to the 15% workforce reduction and cost discipline, Kokai's automation benefits, and continued double-digit growth in CTV internationally. Forward EPS growth estimates rank in the 95th percentile of the ORTEX universe, though that extraordinary ranking reflects low prior-year comparables as much as genuine acceleration. The ORTEX short score has drifted down from 54.5 in late September to 52.9 this week, moderately bearish but no longer at extremes.

Past earnings reactions provide sobering context. The three most recent prints each produced a one-day decline of more than 24%, with the August 2026 result triggering a 27% drop and a 23% loss over the following five sessions. Whatever direction the October 19 report takes, the stock has demonstrated it can move violently in either direction on a single quarter's numbers.

The next nine days narrow to one question: whether Q3 revenue came in at or above the floor the company set with its "at least $650 million" guidance, and what Q4 signals management is prepared to give in the wake of the index demotion, the management turnover, and a consumer-spending backdrop that has not yet stabilised.